These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25189344)

  • 1. Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database.
    Wilson AB; Neogi T; Prout M; Jick S
    Cancer Epidemiol; 2014 Oct; 38(5):544-9. PubMed ID: 25189344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
    Kaplan HG; Malmgren JA; Li CI; Calip GS
    Breast Cancer Res Treat; 2013 Dec; 142(3):629-36. PubMed ID: 24265034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The myelodysplastic syndrome and autoimmunity].
    Laursen SB; Nielsen MØ; Hasselbalch HC
    Ugeskr Laeger; 2009 Sep; 171(37):2639-42. PubMed ID: 19758507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study.
    Kaplan H; Malmgren J; De Roos AJ
    Breast Cancer Res Treat; 2013 Feb; 137(3):863-7. PubMed ID: 23274844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes.
    Kristinsson SY; Björkholm M; Hultcrantz M; Derolf ÅR; Landgren O; Goldin LR
    J Clin Oncol; 2011 Jul; 29(21):2897-903. PubMed ID: 21690473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune diseases and myelodysplastic syndromes.
    Komrokji RS; Kulasekararaj A; Al Ali NH; Kordasti S; Bart-Smith E; Craig BM; Padron E; Zhang L; Lancet JE; Pinilla-Ibarz J; List AF; Mufti GJ; Epling-Burnette PK
    Am J Hematol; 2016 May; 91(5):E280-3. PubMed ID: 26875020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between myelodysplastic syndromes and autoimmune disorders.
    Zhao S; Mao H; Wang H; Yu J
    Zhonghua Xue Ye Xue Za Zhi; 2002 Jun; 23(6):311-3. PubMed ID: 12411063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and risk factors for infections in myelodysplastic syndromes.
    Sullivan LR; Sekeres MA; Shrestha NK; Maciejewski JP; Tiu RV; Butler R; Mossad SB
    Transpl Infect Dis; 2013 Dec; 15(6):652-7. PubMed ID: 24010918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
    Montoro J; Gallur L; Merchán B; Molero A; Roldán E; Martínez-Valle F; Villacampa G; Navarrete M; Ortega M; Castellví J; Saumell S; Bobillo S; Bosch F; Valcárcel D
    Ann Hematol; 2018 Aug; 97(8):1349-1356. PubMed ID: 29572561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population.
    Lv L; Lin G; Gao X; Wu C; Dai J; Yang Y; Zou H; Sun H; Gu M; Chen X; Fu H; Bao L
    Am J Hematol; 2011 Feb; 86(2):163-9. PubMed ID: 21264898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database.
    Shukron O; Vainstein V; Kündgen A; Germing U; Agur Z
    Am J Hematol; 2012 Sep; 87(9):853-60. PubMed ID: 22674538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks of myeloid malignancies in patients with autoimmune conditions.
    Anderson LA; Pfeiffer RM; Landgren O; Gadalla S; Berndt SI; Engels EA
    Br J Cancer; 2009 Mar; 100(5):822-8. PubMed ID: 19259097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.
    Péan de Ponfilly-Sotier M; Jachiet V; Benhamou Y; Lahuna C; De Renzis B; Kottler D; Voillat L; Dimicoli-Salazar S; Banos A; Chauveheid MP; Alexandra JF; Grignano E; Liferman F; Laborde M; Broner J; Michel M; Lambotte O; Laribi K; Venon MD; Dussol B; Martis N; Thepot S; Park S; Couret D; Roux-Sauvat M; Terriou L; Hachulla E; Bally C; Galland J; Allain JS; Parcelier A; Peterlin P; Cohen-Bittan J; Regent A; Ackermann F; Le Guen J; Algrin C; Charles P; Daguindau E; Puechal X; Dunogue B; Blanchard-Delaunay C; Beyne-Rauzy O; Grobost V; Schmidt J; Le Gallou T; Dubos-Lascu G; Sonet A; Denis G; Roy-Peaud F; Fenaux P; Adès L; Fain O; Mekinian A;
    Clin Exp Rheumatol; 2022 Jul; 40(7):1336-1342. PubMed ID: 35579092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation.
    Mukherjee S; Reddy CA; Ciezki JP; Abdel-Wahab M; Tiu RV; Copelan E; Advani AA; Saunthararajah Y; Paulic K; Hobson S; Maciejewski JP; Bolwell BJ; Kalaycio M; Dreicer R; Klein EA; Sekeres MA
    J Natl Cancer Inst; 2014 Mar; 106(3):djt462. PubMed ID: 24577815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes.
    Linabery AM; Roesler MA; Richardson M; Warlick ED; Nguyen PL; Cioc AM; Poynter JN
    Cancer Epidemiol; 2022 Feb; 76():102090. PubMed ID: 34995873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS).
    Yarosh R; Roesler MA; Murray T; Cioc A; Hirsch B; Nguyen P; Warlick E; Poynter JN
    Cancer Causes Control; 2021 Mar; 32(3):241-250. PubMed ID: 33392905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features and survival analysis in primary myelodysplastic syndromes patients with immunological abnormalities].
    Li B; Xu ZF; Cui R; Chen YD; Su T; Zhang TJ; Fang LW; Zhang HL; Qin TJ; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):527-31. PubMed ID: 22967411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is thyroid autoimmunity a risk factor for developing primary myelodysplastic syndrome?
    Dalamaga M; Lekka A; Karmaniolas K; Stathopoulou E; Dionyssiou-Asteriou A
    Cancer Causes Control; 2008 May; 19(4):371-8. PubMed ID: 18064534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.